ARTICLE | Company News

Amylin, Eli Lilly sales and marketing update

August 1, 2011 7:00 AM UTC

Amylin reported in its 2Q11 earnings that partner Eli Lilly launched once-weekly Bydureon exenatide in the U.K. in July to treat Type II diabetes. The launch triggered a $15 million milestone payment to Amylin. The wholesale acquisition cost for a four-week supply containing 4 vials of 2 mg Bydureon is £73.36 ($119.48). ...